Liraglutide – Think T2DM

NEJM — Weighing Risks and Benefits of Liraglutide — The FDA’s Review of a New Antidiabetic Therapy

On January 25, 2010, the FDA approved liraglutide, a glucagon-like-peptide-1 (GLP-1) receptor agonist that can be taken once daily to improve glycemic control in adults with type 2 diabetes.

Leave a comment